Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AMLX Amylyx Pharmaceuticals

Market Closed 06-18 16:00:00 EDT

15.67

+0.42

+2.75%

盘后15.67

+0.000.00%

19:20 EDT

High16.20	Low15.32	Vol1.29M
Open15.32	D1 Closing15.25	Amplitude5.80%
Mkt Cap1.74B	Tradable Cap1.03B	Total Shares111.19M
T/O20.22M	T/O Rate1.98%	Tradable Shares65.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AMLX","market":"US","secType":"STK","nameCN":"Amylyx Pharmaceuticals","latestPrice":15.67,"timestamp":1781812800000,"preClose":15.25,"halted":0,"volume":1293015,"hourTrading":{"tag":"盘后","latestPrice":15.67,"preClose":15.67,"latestTime":"19:20 EDT","volume":106167,"amount":1663669.188,"timestamp":1781824841611,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.027540983606557372,"floatShares":65449399,"shares":111186317,"eps":-1.48947,"marketStatus":"Market Closed","change":0.42,"latestTime":"06-18 16:00:00 EDT","open":15.315,"high":16.2,"low":15.315,"amount":20217349.7973,"amplitude":0.058033,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.48947,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1641531600000,"exchange":"NASDAQ","adjPreClose":15.25,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":15.5,"preClose":15.25,"latestTime":"09:29 EDT","volume":2503,"amount":38495.701975,"timestamp":1781789372073,"change":0.25,"changeRate":0.016393,"amplitude":0.030164},"postHourTrading":{"tag":"盘后","latestPrice":15.67,"preClose":15.67,"latestTime":"19:20 EDT","volume":106167,"amount":1663669.188,"timestamp":1781824841611,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7202634095366014,"impliedVol":0.688,"impliedVolPercentile":0.749},"requestUrl":"/m/hq/s/AMLX/tweets","defaultTab":"tweets","newsList":[{"id":"2644085611","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644085611","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644085611?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:40","pubTimestamp":1781786435,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-amylyx-pharmaceuticals-inc-amlx-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-amylyx-pharmaceuticals-inc-amlx-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMLX","BK4139","BK4585","LU0029874061.USD","BK4535","LABU","BK4007","XLV","BK4588","BK4121","HCSG","BK4581","ABCL","XBI","ZYME","LU0128526141.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643757879","title":"Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643757879","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643757879?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:40","pubTimestamp":1781613612,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-amylyx-pharmaceuticals-inc-amlx-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-amylyx-pharmaceuticals-inc-amlx-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4581","HCSG","BK4007","LABU","ASND","AMLX","LU0109394709.USD","BK4139","BK4585","LU0889565916.HKD","BK4137","XBI","XLV","LU0128526141.USD","BK4588","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641482816","title":"Amylyx to present avexitide Phase 3 LUCIDITY trial design poster at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2641482816","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641482816?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:00","pubTimestamp":1780923632,"startTime":"0","endTime":"0","summary":"Amylyx will present two posters at the Endocrine Society’s ENDO 2026 meeting in Chicago, June 13-16, 2026.Data on the U.S. burden of post-bariatric hypoglycemia is scheduled for June 14, 2026.Trial-design work for the Phase 3 LUCIDITY study of avexitide in post-bariatric hypoglycemia is slated for June 15, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL3XxKFZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641162575","title":"Amylyx Pharmaceuticals shareholders elect Milne, Fonteyne as Class II directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641162575","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641162575?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:09","pubTimestamp":1780603790,"startTime":"0","endTime":"0","summary":"Amylyx held its annual shareholder meeting on June 4, 2026.Shareholders backed the director slate, electing George Mclean Milne Jr. and Paul Fonteyne to three-year terms ending in 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL9NmPwg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639113806","title":"HELIOS Wolfram Data And Patient Insights Could Be A Game Changer For Amylyx Pharmaceuticals (AMLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639113806","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639113806?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:14","pubTimestamp":1779999246,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals recently reported that 24-week and 48-week results from its Phase 2 open-label HELIOS trial of AMX0035 in adults with Wolfram syndrome were published in The Journal of Clinical Investigation, showing sustained improvements in beta cell function, glycemic control and disease stabilization with a mild to moderate safety profile.\nBeyond the clinical data, qualitative interviews highlighted patient-reported improvements in diabetes and vision problems, underscoring the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/helios-wolfram-data-and-patient-insights-could-be-a-game-cha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/helios-wolfram-data-and-patient-insights-could-be-a-game-cha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638822540","title":"Amylyx director Karen Firestone acquires $51,338 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2638822540","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638822540?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:00","pubTimestamp":1779825650,"startTime":"0","endTime":"0","summary":"Amylyx director Karen Firestone bought 3,800 common shares at USD 13.51 each.Firestone’s direct holding rose to 66,900 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL2zQkxG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Amylyx director Karen Firestone acquires $51,338 of common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637548453","title":"Do HELIOS Data Shift Amylyx (AMLX) From ALS Setback To Broader Rare-Disease Strategy Reboot?","url":"https://stock-news.laohu8.com/highlight/detail?id=2637548453","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637548453?lang=en_us&edition=fundamental","pubTime":"2026-05-22 02:33","pubTimestamp":1779388401,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals recently reported that 24- and 48-week results from its Phase 2 open-label HELIOS trial of AMX0035 in adults with Wolfram syndrome were published in The Journal of Clinical Investigation, showing improved pancreatic beta cell function, better glycemic control, and a consistent safety profile.\nBecause Wolfram syndrome affects only about 3,000 people in the U.S. with no FDA-approved treatments, these peer-reviewed data highlight AMX0035’s potential to address a rare,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/do-helios-data-shift-amylyx-amlx-from-als-setback-to-broader","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/do-helios-data-shift-amylyx-amlx-from-als-setback-to-broader","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635317590","title":"Amylyx announces publication of Phase 2 open-label HELIOS trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2635317590","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635317590?lang=en_us&edition=fundamental","pubTime":"2026-05-16 01:48","pubTimestamp":1778867306,"startTime":"0","endTime":"0","summary":"Amylyx (AMLX) Pharmaceuticals announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fix...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-announces-publication-of-phase-2-open-label-helios-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-announces-publication-of-phase-2-open-label-helios-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635036780","title":"Amylyx posts Phase 2 HELIOS data showing AMX0035 benefits in Wolfram syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2635036780","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635036780?lang=en_us&edition=fundamental","pubTime":"2026-05-16 00:12","pubTimestamp":1778861536,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals announced peer-reviewed publication of Week 24 and Week 48 results from Phase 2 open-label HELIOS trial of AMX0035 in adults with Wolfram syndrome; portions of data were previously presented at medical meetings.Results indicated stabilization or improvement across measures tied to disease progression, including pancreatic function, glucose control, vision, and overall symptom burden.Drug was generally well tolerated, consistent with earlier safety disclosures, with no treatment-related serious adverse events reported.Company is working with FDA on Phase 3 trial in Wolfram syndrome; additional longer-term HELIOS data are expected at an upcoming scientific meeting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL5mHL1t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635036222","title":"Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label Helios Trial Data for Amx0035 in the Journal of Clinical Investigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2635036222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635036222?lang=en_us&edition=fundamental","pubTime":"2026-05-16 00:12","pubTimestamp":1778861520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA5YCYBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634287427","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2634287427","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634287427?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:50","pubTimestamp":1778507414,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lipocine (LPCN), Amylyx Pharmaceuticals Inc (AMLX) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-160?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-160?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4581","BK4137","BK4007","BLSX","LABU","AMLX","LU0128526141.USD","BK4112","LPCN","BLSG","BK4585","LU0029874061.USD","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634440448","title":"Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634440448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634440448?lang=en_us&edition=fundamental","pubTime":"2026-05-10 21:50","pubTimestamp":1778421041,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amylyx-pharmaceuticals-inc-amlx-bioage-labs-inc-bioa-and-pharvaris-phvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amylyx-pharmaceuticals-inc-amlx-bioage-labs-inc-bioa-and-pharvaris-phvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHVS","AMLX","HCSG","LU0128526141.USD","LU0029874061.USD","XBI","BIOA","XLV","BK4585","LABU","BK4007","BK4581","BK4137","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195103077","title":"Stock Track | Amylyx Pharmaceuticals Plummets 8.16% Intraday on Wider-Than-Expected Q1 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1195103077","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195103077?lang=en_us&edition=fundamental","pubTime":"2026-05-08 00:36","pubTimestamp":1778171778,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals' stock plummeted 8.16% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.The biotech firm reported a net loss of $41.3...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633075124","title":"Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633075124","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633075124?lang=en_us&edition=fundamental","pubTime":"2026-05-08 00:33","pubTimestamp":1778171620,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryAmylyx Pharmaceuticals Inc AMLX.OQ reported a quarterly adjusted loss of 37 cents per share for the quarter ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K2J8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633146434","title":"Amylyx Pharmaceuticals Q1 net loss widens more than expected on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2633146434","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633146434?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:22","pubTimestamp":1778152935,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals Q1 net loss widens more than expected on higher R&D costsOverviewU.S. biotech firm's Q1 net loss widened, missing analyst expectationsQ1 adjusted EPS missed analyst consensusHig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K0L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633466001","title":"Earnings Flash (AMLX) Amylyx Posts Q1 Loss $0.37 a Share, vs. FactSet Est of $0.35 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2633466001","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633466001?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:19","pubTimestamp":1778152756,"startTime":"0","endTime":"0","summary":"Earnings Flash (AMLX) Amylyx Posts Q1 Loss $0.37 a Share, vs. FactSet Est of $0.35 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145993","title":"Amylyx Pharma Q1 EPS $(0.37), Inline, Cash, Cash Equivalents, And Short-Term Investments Were $279.8M, With Expected Cash Runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145993","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145993?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:07","pubTimestamp":1778152077,"startTime":"0","endTime":"0","summary":"Amylyx Pharma Q1 EPS $(0.37), Inline, Cash, Cash Equivalents, And Short-Term Investments Were $279.8M, With Expected Cash Runway into 2028","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/AMLX","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633143027","title":"Amylyx Q1 net loss widens to $41.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633143027","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633143027?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:02","pubTimestamp":1778151762,"startTime":"0","endTime":"0","summary":"Amylyx posted a net loss of USD 41.3 million, or USD 0.37 per share, for first-quarter 2026, widening from USD 35.9 million, or USD 0.42 per share, a year earlier.R&D expense rose to USD 27.6 million from USD 22.1 million, driven by higher avexitide development spending; results also included USD 4 million of milestone payments to Gubra tied to selection and handover of AMX0318.SG&A edged up to USD 16.2 million from USD 15.7 million on higher consulting and professional services.Cash, cash equivalents, and short-term investments fell to USD 279.8 million at March 31 from USD 317 million at year-end, with runway expected to fund operations through potential avexitide commercialization and into 2028.Enrollment completed in Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, with topline data anticipated in Q3 2026; management said regulatory and commercial readiness work has started ahead of a potential 2027 launch if approved.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL61zbM5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432631","title":"BRIEF-Amylyx Pharmaceuticals Q1 EPS USD -0.37 Vs. IBES Estimate USD -0.33","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432631","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432631?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151648,"startTime":"0","endTime":"0","summary":"May 07  - Amylyx Pharmaceuticals Q1 operating expenses USD 43.779 million.Q1 net income USD -41.284 million vs. IBES estimate USD -37.4 million. Q1 operating income USD -43.779 million vs. IBES estimate USD -41.6 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXF0BDD8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145695","title":"Amylyx Pharmaceuticals Inc - Cash Runway Expected to Fund Operations Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145695","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145695?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXF0BDD8:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amylyx.com","stockEarnings":[{"period":"1week","weight":0.1265},{"period":"1month","weight":0.23},{"period":"3month","weight":0.1347},{"period":"6month","weight":0.3037},{"period":"1year","weight":2.0725},{"period":"ytd","weight":0.2972}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.074034},{"month":2,"riseRate":0.6,"avgChangeRate":0.089231},{"month":3,"riseRate":0.2,"avgChangeRate":-0.324118},{"month":4,"riseRate":0.4,"avgChangeRate":-0.019949},{"month":5,"riseRate":0.2,"avgChangeRate":-0.057575},{"month":6,"riseRate":0.8,"avgChangeRate":0.296282},{"month":7,"riseRate":1,"avgChangeRate":0.206362},{"month":8,"riseRate":0.5,"avgChangeRate":0.025088},{"month":9,"riseRate":0.75,"avgChangeRate":0.218209},{"month":10,"riseRate":0.75,"avgChangeRate":0.212399},{"month":11,"riseRate":0.75,"avgChangeRate":0.011294},{"month":12,"riseRate":0.25,"avgChangeRate":-0.127185}],"exchange":"NASDAQ","name":"Amylyx Pharmaceuticals","nameEN":"Amylyx Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amylyx Pharmaceuticals(AMLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amylyx Pharmaceuticals,AMLX,Amylyx Pharmaceuticals股票,Amylyx Pharmaceuticals股票老虎,Amylyx Pharmaceuticals股票老虎国际,Amylyx Pharmaceuticals行情,Amylyx Pharmaceuticals股票行情,Amylyx Pharmaceuticals股价,Amylyx Pharmaceuticals股市,Amylyx Pharmaceuticals股票价格,Amylyx Pharmaceuticals股票交易,Amylyx Pharmaceuticals股票购买,Amylyx Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amylyx Pharmaceuticals(AMLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}